Value of S100A8 in evaluating the prognosis of children with acute lymphoblastic leukemia.
- Author:
Mei-Fei OUYANG
1
;
Dan WANG
;
Ying-Ting LIU
;
Lin-Yong XU
;
Ming-Yi ZHAO
;
Xiao-Cheng YIN
;
Min XIE
;
Liang-Chun YANG
;
Ming-Hua YANG
Author Information
1. Department of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008, China. yamahua123@163.com.
- Publication Type:Journal Article
- MeSH:
Calgranulin A;
metabolism;
Child;
Disease-Free Survival;
Humans;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Prognosis;
Retrospective Studies
- From:
Chinese Journal of Contemporary Pediatrics
2019;21(4):359-364
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the association between S100A8 expression and prognosis in children with acute lymphoblastic leukemia (ALL).
METHODS:The clinical data of 377 children with ALL who were treated with the CCLG-2008-ALL regimen were retrospectively reviewed. ELISA and PCR were used to measure serum protein levels and mRNA expression of S100A8. The Kaplan-Meier method was used for survival analysis and a Cox regression analysis was also performed.
RESULTS:The children were followed up for 56 months, and the overall survival rate of the 377 children was 89.1%. The prednisone good response group had significantly lower S100A8 protein and mRNA levels than the prednisone poor response group (P<0.01). In the children with standard or median risk, both S100A8 protein and mRNA levels were associated with event-free survival rate (P<0.05). There were significant differences in S100A8 protein and mRNA levels between the children with different risk stratifications (P<0.01). The children who experienced events had significantly higher S100A8 protein and mRNA levels than those who did not (P<0.01). The Kaplan-Meier survival analysis and the Cox regression model suggested that S100A8 overexpression was an independent risk factor for the prognosis of children with ALL.
CONCLUSIONS:High S100A8 expression may be associated with the poor prognosis of children with ALL and is promising as a new marker for individualized precise treatment of children with ALL.
